Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
IPO Year:
Exchange: NASDAQ
Website: grifols.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/12/2024 | Hold → Sell | Deutsche Bank | |
4/12/2023 | Equal-Weight → Overweight | Morgan Stanley | |
3/3/2023 | Overweight → Equal-Weight | Morgan Stanley | |
2/16/2023 | Underweight → Equal Weight | Barclays | |
1/18/2023 | Hold → Buy | Jefferies | |
4/8/2022 | Equal-Weight | Morgan Stanley | |
11/5/2021 | Buy → Hold | Deutsche Bank | |
10/19/2021 | Overweight → Underweight | Barclays | |
10/6/2021 | Neutral → Buy | Citigroup |
The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs GigaGen's recombinant polyclonals are part of Grifols' robust innovation strategy and commitment to delivering the next generation of antibody drugs for patients and healthcare professionals SAN CARLOS, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint-resistant cancers, and a subsidiary of Grifols, announced today that it has been awarded a contract by the Biomedical Adva
GIGA-2339 is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic hepatitis B virus (HBV) infection; trial initiation expected in Q4 2024 Containing more than 1,000 fully human recombinant anti-HBV antibodies, GIGA-2339 reproduces the human body's natural immune response GigaGen's recombinant polyclonals are part of Grifols' robust innovation strategy and commitment to delivering the next generation of antibody drugs for patients and healthcare professionals SAN CARLOS, Calif. , July 31, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infec
XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go straight to SCIg without initial intravenous therapy Approval, which also includes biweekly dosing, follows phase 4 study data demonstrating comparable total Ig levels when administering XEMBIFY every two weeks versus weekly The expanded label for XEMBIFY provides added flexibility and convenience for patients with primary humoral immunodeficiencies Increasing adoption of XEMBIFY is part of Grifols' broader Ig business strategy focused on treating immunodeficiencies, which represent more than half of the total Ig market and whose growth is e
Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S. as part of a broader Group channel strategy, with Grifols focusing on continued growth of its current portfolio for this market It adds to Grifols' strong franchise of intravenous and subcutaneous immunoglobulins to meet growing patient demand for these therapeutics Yimmugo will be followed by other proteins in the pipeline, including fibrinogen and trimodulin, both in late-stage development BARCELONA, Spain, July 01, 2024 (GLOBE NEWSWIRE) -- Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of th
With today's announcement of the transaction completion, Grifols and Haier Group will work together through Shanghai RAAS (SRAAS) to drive synergies that enhance China's healthcare systemThrough a share purchase agreement Grifols has sold a 20% equity stake in SRAAS to Haier Group for RMB 12.5 billion (approximately EUR 1.6 billion)Grifols and SRAAS extend their exclusive albumin distribution agreement over the next 10 years, and SRAAS has the option to prolong it through 2044Grifols will use all proceeds to comply with its commitment to deleverage BARCELONA, Spain, June 18, 2024 (GLOBE NEWSWIRE) -- Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufa
With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous immunoglobulins to meet strong demand Yimmugo, already approved for production and marketing in Europe, is the first U.S.-approved medicine in Biotest's portfolio and is manufactured with an innovative process at Biotest's new FDA-certified ‘Next Level' facility U.S. approval of Yimmugo paves the way for other Biotest proteins in late-stage development, including fibrinogen and trimodulin Launching Yimmugo in the U.S. will over time significantly add to Grifols Group sales and underpins its future growth strategy BARCELONA, Spain, June 17, 2024 (GLOBE NEWSWIRE) -- Grifols ((MCE:GRF,
GIGA-564 is a differentiated anti-CTLA-4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with CTLA-4 blockade Researchers from the National Cancer Institute will conduct the Phase 1 trial, as established in a recently signed Cooperative Research and Development Agreement (CRADA) SAN CARLOS, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that the first patient has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability
BARCELONA, Spain, April 19, 2024 /PRNewswire/ -- Grifols, S.A. ("Grifols") ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report on Form 20-F provides investors with an overview of the company's governance practices, including information about the Board of Directors and its committees, executive compensation, and risk management. This information is critical for stakeholders to make informed decisions about investing in the company,
The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The flagship Grifols campus is a touchstone of Grifols' leadership in plasma therapeutics, producing about 40% of the company's total medicinal output globally and helping enhance the quality of life of patients all over the worldAn engineering masterwork, the Clayton site is a model for new Grifols plants while its environmental credentials, including a wildlife habitat, make it a standout in sustainability BARCELONA, Spain, April 18, 2024 (GLOBE NEWSWIRE) -- Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:GRFS),
Grifols' in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections Arboviruses are a growing emerging threat, with changes in climate and increasing global connectivity making the geographic spread more prevalent CE mark for Grifols' Procleix ArboPlex Assay reinforces the company's leadership in transfusion medicine and commitment to ensuring the safety of the world's blood supply BARCELONA, Spain, April 04, 2024 (GLOBE NEWSWIRE) -- Grifols ((MCE: GRF, NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines and innovative diagnostic solutions, today announced that its new Procleix ArboPlex Assay h
SC 13G/A - Grifols SA (0001438569) (Subject)
SC 13G - Grifols SA (0001438569) (Subject)
BARCELONA, Spain, Jan. 4, 2022 /PRNewswire/ -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today announced the acquisition of its first donation center in Canada as part of the company's commitment to increase the availability of lifesaving plasma medicines in the country. In a share-purchase agreement, Grifols Canada Therapeutics Inc has acquired Prometic Plasma Resources Inc's (PPR) donation center in Winnipeg from Kedrion for USD 4 million in cash. With the center, Grifols furthers
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
Deutsche Bank downgraded Grifols, S.A. from Hold to Sell
Morgan Stanley upgraded Grifols, S.A. from Equal-Weight to Overweight
Morgan Stanley downgraded Grifols, S.A. from Overweight to Equal-Weight
Barclays upgraded Grifols, S.A. from Underweight to Equal Weight
Jefferies upgraded Grifols, S.A. from Hold to Buy
Morgan Stanley initiated coverage of Grifols, S.A. with a rating of Equal-Weight
Deutsche Bank downgraded Grifols from Buy to Hold
Barclays downgraded Grifols, S.A. from Overweight to Underweight
Citigroup upgraded Grifols, S.A. from Neutral to Buy
Deutsche Bank upgraded Grifols, S.A. from Hold to Buy
BARCELONA, Spain, April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report under Form 20-F is a critical component of the company's commitment to transparency and accountability. The filing of the annual report provides investors with an overview of the company's governance practices, including informa
Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is designated as Chairperson of Honor in recognition of his numerous contributionsSteven F. Mayer, former Co-Head of Global Private Equity and Chairman of the Investment Committee of private investment firm Cerberus Capital Management, L.P., with more than 10 years serving as a Grifols independent board member, is appointed as Executive ChairpersonChanges further evidence of the Board of Directors' focus on strategic objectives, operational excellence, and deleveraging balance sheetBARCELONA, Spain, Oct. 3, 2022 /PRNewswire/ -- Grifols (MCE: GRF)
SAN CARLOS, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced the appointment of Dr. César Cerezo M.D., Ph.D., as chief medical officer. He will be responsible for leading and providing strategic direction to the clinical development and medical teams. "Dr. Cerezo brings to Alkahest robust and broad experience both as a practicing and research physician, and as an experienced pharmaceutical and biotechnology industry leader. Having played a significant role in the advancement of multiple clinical developmen
- Reuters
Shares of Arhaus, Inc. (NASDAQ:ARHS) fell sharply during Monday's session. Jefferies analyst Jonathan Matuszewski downgraded Arhaus from Buy to Hold and lowered the price target from $22 to $16. Arhaus shares dipped 7.9% to $14.55 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Morphic Holding, Inc. (NASDAQ:MORF) shares jumped 75% to $55.72 after Eli Lilly agreed to buy the company for $57 per share in cash. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) climbed 71% to $6.97 after jumping around 50% on Friday. SRIVARU Holding Limited (NASDAQ:SVMH) shares climbed 61.3% to $0.2549 after the company announced the deployment of advanced
In a regulatory filing, Grifols SA (NASDAQ:GRFS) said that Brookfield Capital has confirmed that it has engaged in preliminary discussions with Grifols’s key shareholders regarding a potential joint offer to delist the company’s shares from the Spanish stock exchanges and NASDAQ. Brookfield and the shareholders have signed an exclusivity agreement to explore this possibility further and requested access to certain company information to conduct due diligence. Also Read: Spanish Healthcare Firm Grifols’ Reputational Damage and Debt Woes: European Central Bank Probes Lenders. According to the information provided to the Board of Directors, Brookfield, and the Grifols family shareholde
U.S. stocks were higher, with the Dow Jones index surging around 200 points on Monday. Shares of Corning Incorporated (NYSE:GLW) rose sharply during Monday's session after the company increased its second-quarter core sales guidance. The company said it now projects core sales to be approximately $3.6 billion (vs. consensus of $3.41 billion), an increase from the previous guidance of $3.4 billion. Core EPS is expected to reach the high end of, or slightly exceed, the management's guided range of $0.42 to $0.46 (vs. estimate of $0.45). Corning shares jumped 9.4% to $42.05 on Monday. Here are some other big stocks recording gains in today’s session. Morphic Holding, Inc. (NASDA
GRFS: 31% | Brookfield Confirms It Held Exploratory Discussions With Certain Reference Shareholders Of Co In Relation To A Potential Joint Offer For Grifols' Shares To Delist Them SEDG: 7% | SolarEdge Technologies shares are trading higher after B of A Securities upgraded the stock from Underperform to Neutral. CRKN: 21% | Crown Electrokinetics shares are trading higher after the company entered into a contracting agreement with Paramount Networks, expanding operations in Arizona and Oregon. Additionally, the company revised its Q3 guidance from $7M-$8M to $8M-$9M.
In relation to certain rumors appearing in the media about a potential transaction involving Grifols, S.A. ("Grifols" or the "Company"), Brookfield confirms that it has held exploratory conversations with certain key shareholders of the Company regarding a potential joint offer for the shares of Grifols to delist them from the Spanish stock exchanges and NASDAQ. Brookfield and various entities that hold the shares of these key shareholders (i.e., Scranton Enterprises B.V., Deria S.L., Ponder Trade S.L., and Ralledor Holding Spain, S.L. – the "Key Shareholders") have signed an exclusivity agreement to continue evaluating the potential transaction. On July 7, the Key Shareholders and Brookfiel
Shares of Paramount Global (NASDAQ:PARAA) rose sharply in today's pre-market trading. Paramount Global and Skydance Media inked a definitive agreement to create a new entity, "New Paramount," in a $28 billion merger deal. Paramount Global shares jumped 7.5% to $22.00 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Shapeways Holdings, Inc. (NASDAQ:SHPW) rose 93.7% to $0.4068 in pre-market trading after dipping 22% on Friday. Inspire Veterinary Partners, Inc. (NASDAQ:IVP) shares rose 52.3% to $2.27 in pre-market trading after gaining 8% on Friday. Dynatronics Corporation (NASDAQ:DYNT) shares rose 36.6% to $0.29 in pre-market trading
Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S. as part of a broader Group channel strategy, with Grifols focusing on continued growth of its current portfolio for this market It adds to Grifols' strong franchise of intravenous and subcutaneous immunoglobulins to meet growing patient demand for these therapeutics Yimmugo will be followed by other proteins in the pipeline, including fibrinogen and trimodulin, both in late-stage development